盘龙药业：PLJT-001洛索洛芬钠凝胶贴膏获境内生产药品注册上市许可受理通知书

Core Viewpoint - The company, Panlong Pharmaceutical (002864.SZ), has received a notice of acceptance for the marketing authorization application of its research product, Loxoprofen Sodium Gel Patch, from the National Medical Products Administration (NMPA) [1] Group 1: Product Information - Loxoprofen Sodium Gel Patch (PLJT-001) is designed to treat osteoarthritis, muscle pain, and swelling or pain after injuries [1] - The active ingredient, Loxoprofen Sodium, is a non-steroidal anti-inflammatory drug (NSAID) with significant anti-inflammatory and analgesic effects, particularly strong analgesic properties [1] - The mechanism of action involves the inhibition of prostaglandin synthesis, targeting cyclooxygenase [1] Group 2: Product Features - Loxoprofen Sodium is a prodrug that is absorbed through the skin and converted into an active metabolite, trans-OH, to exert its effects [1] - The gel patch is characterized by low irritation and allergenic potential, strong adhesion, and a lightweight formulation that allows for good skin extensibility [1] - It can be applied to active joints without affecting daily activities, significantly enhancing medication comfort and convenience [1]